ライフサイエンスコーパス: phase III

1 ad by comparing the results from phase I and phase III.

2 velation of the mysterious structure of blue phase III.

3 optical, and photonic devices based on blue phase III.

4 ncyclopedia of DNA Elements (ENCODE) project phase III.

5 the steady state mimicking the experimental phase III.

6 ute maternal hyperoxia with 100% oxygen; and phase III, 5.6-minute return to resting state.

7 In the final phase (phase III), a public data set of multimodality images (C

8 The prospective randomized phase III ABCSG-28 POSYTIVE trial evaluated median survi

9 The integration of efficacy data across the Phase III ABSSSI studies is presented here and allows fo

10 Phase III adjuvant trials have reported significant bene

11 We performed a meta-analysis of the 4 phase III AF trials of the currently available NOACs ver

12 The phase III ALLY-3+ study (N = 50) evaluated DCV-SOF with

13 ic nature of the transitions from phase I to phases III and IV.

14 d vs. dupilumab, patient-level data from the Phase III benralizumab OCS-sparing trial, ZONDA, were we

15 ween no boost and a 16-Gy boost in the EORTC phase III "boost no boost" trial (1989-1996).

16 tured polymer scaffold of the amorphous blue phase III (BPIII) of cholesteric liquid crystals (LCs),

17 ctive of the randomized, placebo-controlled, phase III C-EDGE IBLD study was to assess the safety and

18 nd provide an overview of recently published phase III cardiovascular trials using primary composite

19 ients, but these are underrepresented in the phase III clinical studies that established the current

20 the only vaccine platform that has completed Phase III clinical studies, it is imperative to gain a b

21 a samples were collected as part of a large, phase III clinical trial (Mitotarget/TRO19622) at months

22 In a prospective, randomized phase III clinical trial evaluating the activity of tras

23 adipine is currently undergoing testing in a phase III clinical trial in early PD.

24 Methods: We conducted a substudy of the phase III clinical trial of flurpiridaz (n = 750) and st

25 to be useful in cancer immunotherapy, but a phase III clinical trial of the most advanced IDO1 inhib

26 igh-dose octreotide long-acting release in a phase III clinical trial of well-differentiated midgut N

27 Phase III clinical trial results have shown that omadacy

28 However, negative phase III clinical trial results of the IDO1 inhibitor e

29 4 clinical trial.IMPORTANCE Though the RV144 phase III clinical trial showed promise that an effectiv

30 onditioning blood from patients treated in a phase III clinical trial that randomly assigned adult pa

31 A multicenter randomized phase III clinical trial validating these results in a l

32 nutrient interactions was highlighted when a phase III clinical trial was terminated due to severe ad

33 ization protocol mimicking that of the RV144 phase III clinical trial was used.

34 idated as predictive of benefit from RT in a phase III clinical trial with patients randomly assigned

35 om 1095 patients treated over 24 months in a phase III clinical trial with randomization to 2 drug do

36 prior acute myocardial infarction in a large phase III clinical trial, including 10 061 patients worl

37 igned to improve on the results of the RV144 phase III clinical trial.

38 provides strong rationale for a confirmatory phase III clinical trial.

39 ested as a neuroprotective agent for PD in a phase III clinical trial.

40 adjuvant chemoradiation (NACR) enrolled in a phase III clinical trial.

41 lefamulin, including recent evidence from 2 phase III clinical trials (LEAP 1 and LEAP 2), and discu

42 0) and from Gynecologic Oncology Group (GOG) phase III clinical trials 218 (n = 788) and 262 (n = 557

43 tematic literature review and identified two phase III clinical trials and a randomized phase II dose

44 It is now in phase III clinical trials and is expected to be approved

45 mal studies support the observations made in phase III clinical trials and the clinical development o

46 compound is currently being investigated in phase III clinical trials as a maintenance therapy in pl

47 has not extended to glioblastoma (GBM), with phase III clinical trials assessing anti-PD-1 monotherap

48 currently being assessed in two prospective phase III clinical trials for stratification of therapy.

49 locorticoid receptor antagonist currently in phase III clinical trials for the treatment of chronic k

50 Four phase III clinical trials form the primary evidence base

51 Data from two phase III clinical trials of omalizumab in patients with

52 rresponding analyses from placebo-controlled Phase III clinical trials of the phosphodiesterase type

53 heart failure, and highlights the results of phase III clinical trials of therapies targeting inflamm

54 Among the phase III clinical trials only the RV144 vaccine trial e

55 inflammation in the heart failure setting in phase III clinical trials resulted in neutral effects or

56 This information is required for designing phase III clinical trials using this technique.

57 prostate cancer (mCRPC) who were treated in phase III clinical trials with docetaxel plus prednisone

58 and preclinical data, early clinical trials, phase III clinical trials, and an integrated safety summ

59 clinical testing and has progressed through phase III clinical trials, continued efforts are underwa

60 ine that rigosertib, an anti-cancer agent in phase III clinical trials, kills cancer cells by destabi

61 el-targeted TNFalpha derivative currently in phase III clinical trials, substituted for Y-redirected

62 se of at least 30mg/kg to be investigated in phase III clinical trials.

63 difficult course with 3 compounds failing in phase III clinical trials.

64 In Europe, ferumoxtran-10 is entering phase III clinical trials.

65 ide in Diabetic Macular Edema (FAME) A and B Phase III clinical trials.

66 , a prodrug of which is currently undergoing phase III clinical trials.

67 resistant prostate cancer but was dropped in phase III clinical trials.

68 nt treatments for micrometastatic disease in phase III clinical trials.

69 , a prodrug version of which is currently in phase III clinical trials.

70 A multicenter randomized Phase-III clinical trial validating these results in a l

71 a larger fraction of significant results in phase III compared to phase II.

72 10), intragastric DB switched the origin of phase III contractions from the stomach to the duodenum

73 Motilin-induced phase III contractions have been identified as a hunger

74 Motilin-induced phase III contractions induced hunger feelings through a

75 The impact of pharmacologically induced phase III contractions on the occurrence of hunger peaks

76 peaks and their significant association with phase III contractions was confirmed (P < 0.0001).

77 deep remissions and is now being studied in phase III cooperative group trials.

78 sessing safety and efficacy, CTs, especially phase III CTs, are costly and require rigorous planning

79 was performed using the 1000 Genomes Project Phase III dataset as reference panel.

80 trial had a marker-by-treatment interaction phase III design, with ERCC1 (8F1 antibody) status as a

81 We conducted the phase III double-blind European Organisation for Researc

82 national Group (BIG) conducted a randomized, phase III, double-blind trial, BIG 1-98, which enrolled

83 In X-ACT, a phase III, double-blind, placebo-controlled study, CSU p

84 BIG 1-98 is a four-arm, phase III, double-blind, randomized trial comparing adju

85 blind trials (Phase IIb: P007 [NCT01632345]; Phase III: DRIVE-FORWARD [NCT02275780] and DRIVE-AHEAD [

86 values of primary outcomes for phase II and phase III drug trials reported to the ClinicalTrials.gov

87 n expression for all targets of marketed and phase III drugs across a diverse collection of normal hu

88 ve clinical study differs from a traditional phase III efficacy and safety study in the development o

89 umatic brain injury and the feasibility of a Phase III efficacy study.

90 rent ovarian cancer who were enrolled in the phase III ENGOT-OV16/NOVA trial.

91 event profile was consistent with that from phase III enzalutamide trials.

92 In an update of the randomized, open-label, phase III European Mantle Cell Lymphoma (MCL) Elderly tr

93 arch; (f) challenges planning and conducting phase III (field) studies and the future role of Allerge

94 A second phase III Food and Drug Administration trial is ongoing.

95 pletely the excess of significant results in phase III for trials conducted by large industry sponsor

96 perties of the practically unobservable blue phase III have eluded scientists for more than a century

97 ric acute promyelocytic leukemia (APL) was a phase III historically controlled trial to determine the

98 In this Phase III, individually randomized, controlled, double-b

99 CALGB 80101 (Alliance; Phase III Intergroup Trial of Adjuvant Chemoradiation Af

100 In a phase III, international, double-blind, placebo-controll

101 In a pooled analysis of three phase III IPF clinical trials, patients receiving pirfen

102 over 52 weeks using data derived from three phase III IPF clinical trials.

103 s and Methods This secondary analysis of the phase III METEOR trial conducted between 2013 and 2014 i

104 In the final validation phase (phase III), most of the 169 standardized features could

105 In this phase III multicenter trial, 307 patients with OC were r

106 ive intent were included in our double-blind phase III multicenter trial.

107 o evaluate data from PRODIGE 24/CCTG PA.6, a phase III, multicenter, randomized clinical trial of pos

108 n a subset of patients who participated in a phase III, multicenter, randomized, double-blind, placeb

109 This was a phase III, multicenter, randomized, open-label trial.

110 The GRECCAR-6 trial was a phase III, multicenter, randomized, open-label, parallel

111 Methods GRECCAR6 was a phase III, multicenter, randomized, open-label, parallel

112 end point to substitute for OS to accelerate phase III (neo)adjuvant trials of prostate cancer therap

113 The distribution of enrollment by age in phase III non-ST-segment-elevation acute coronary syndro

114 ective, randomized, multicenter, open-label, phase III noninferiority trial.

115 Results The Update Committee reviewed three phase III noninferiority trials of dosing intervals, one

116 led, open-label, international, multicenter, phase III, noninferiority study.

117 The amorphous blue phase III of cholesteric liquid crystals, also known as

118 ray diffraction of orientational ordering in phase III of solid hydrogen at pressures up to 183 GPa.

119 To better delineate these elements, phase III of the Encyclopedia of DNA Elements (ENCODE) P

120 Here, to address these questions as part of phase III of the Encyclopedia of DNA Elements (ENCODE),

121 e for inclusion that reported results of the phase III, open-label KATHERINE trial.

122 sex-specific meta-analysis was conducted of phase III or IV randomized trials of potent P2Y12 inhibi

123 In the randomized open-label phase III OVHIPEC trial, the addition of hyperthermic in

124 The confirmatory phase III part of the study is ongoing.

125 We performed a post hoc analysis of a phase III placebo-controlled study to identify character

126 In the phase III PlanB trial, RS was prospectively used to defi

127 In this phase III prospective multicenter clinical study, 795 pa

128 Results of a phase III prospective multicentre study of blue light fl

129 Phase III prospective, multicenter, randomized clinical

130 r data, we have designed a cooperative group phase III prospective, randomized trial of conventional

131 amples from patients in the CRITICS trial, a phase III randomized controlled study of perioperative t

132 A phase III randomized controlled trial demonstrated that

133 re review to identify all publicly available phase III randomized controlled trial evidence.

134 Based on evidence from a phase III randomized controlled trial, patients with res

135 to conduct a systematic review of published phase III randomized controlled trials (2007-2020) on sy

136 Recent Data Six phase III randomized controlled trials and expert consen

137 ese encouraging results suggest that larger, phase III randomized controlled trials are in order to c

138 Nine phase III randomized controlled trials met the inclusion

139 ta-analyses, reports of rigorously conducted phase III randomized controlled trials that compared >=

140 Three phase III randomized controlled trials, one phase II tri

141 this focused update, the publication of the phase III randomized MINDACT (Microarray in Node-Negativ

142 To test this hypothesis, we performed a phase III randomized trial comparing MAC with RIC in pat

143 This was a phase III randomized trial in patients with advanced NSC

144 A Phase III randomized trial to assess impact on neurologi

145 Patients and Methods In this phase III randomized trial, we assessed the noninferiori

146 ransplant outcomes following a phase I and a phase III randomized trial.

147 ember 2005 and November 2009 in the PETACC-8 phase III randomized trial.Mismatch repair, BRAF V600E,

148 on sensitivity to standard therapies in two phase III randomized trials that represent the developme

149 ndividual patient data was pooled from three phase III randomized, placebo-controlled studies of pirf

150 We report the results of a multicenter, phase III, randomized open-label trial exploring the ben

151 ysis of overall survival (OS) in GOG-0218, a phase III, randomized trial of bevacizumab in women with

152 This was a phase III, randomized, double-blind, multicenter study t

153 Data were pooled from two phase III, randomized, double-blind, placebo-controlled

154 Twelve-week, phase III, randomized, double-masked, multicenter, place

155 sive multiple sclerosis participating in the phase III, randomized, placebo-controlled, double-blind

156 A Phase III RCT is underway to further investigate safety

157 veals an upward jump at the 5% threshold for phase III results by small industry sponsors.

158 Post hoc analysis of the phase III RIDE and RISE studies of ranibizumab for treat

159 nd predawn Psi reached similar values during phase III (severe drought).

160 ectively reviewed all patients enrolled in a phase III, single-arm trial for low-risk and intermediat

161 alian, multicenter, prospective, randomized, Phase III STEM-AMI OUTCOME trial, 161 ST-segment-elevati

162 requent treatment-emergent adverse events in phase III studies but were not treatment limiting.

163 CDK4/6-selective inhibitor, is currently in phase III studies for ER-positive breast cancer and KRAS

164 l compared with docetaxel in two independent phase III studies in previously treated patients with ad

165 but are frequently followed by unsuccessful phase III studies, highlighting a disconnect in the tran

166 ith stage III CC included in the IDEA France phase III study (ClinicalTrials.gov identifier: NCT00958

167 The OlympiAD Phase III study (NCT02000622) established the clinical b

168 A global phase III study (NCT02312206) has been initiated.

169 A pivotal phase II and a confirmatory phase III study are ongoing.

170 Purpose A phase III study comparing eribulin with dacarbazine in p

171 erformed an open-label randomized controlled phase III study comparing treatment outcome and toxicity

172 ods Southwest Oncology Group (SWOG) S0518, a phase III study conducted in a US cooperative group syst

173 Pneumonia Treatment In the Community (OPTIC) phase III study demonstrated noninferiority of omadacycl

174 s and Methods This randomized, double-blind, phase III study enrolled patients with histologically co

175 This placebo-controlled phase III study evaluated telotristat ethyl in this sett

176 eport the results of OPUS-3 (NCT02284516), a phase III study evaluating the efficacy and safety of li

177 pancreatic NET, the longest OS reported in a phase III study for this population.

178 This phase III study further investigated those findings.

179 oxacin-treated patients) was observed in the phase III study in patients with community-acquired bact

180 All eyes from the VISTA Phase III study in the IAI groups imaged with the Cirrus

181 his was a post hoc analysis of the Edaravone Phase III Study MCI186-19 ('Study 19') to examine the ut

182 A recent randomized phase III study of 719 de novo liver transplant recipien

183 A randomized, double-blind, phase III study of idelalisib (IDELA) plus rituximab ver

184 d the diagnostic performance and safety in a phase III study of patients with SSTR-expressing NETs.

185 In a post hoc analysis of data from a phase III study of the effects of teduglutide on patient

186 e recently published results of a randomized phase III study prompted an update of this guideline.

187 The CONKO-003 phase III study reported a survival benefit with second-

188 In the meantime, Phase III study results suggest investigational epicutan

189 A phase III study to evaluate the longer term effects of o

190 We designed a prospective, randomized, phase III study to test additional interventions to impr

191 the Children's Oncology Group (COG) ANBL0532 phase III study was to assess the effect of increasing l

192 In this multicenter, double-blind, phase III study, 418 patients with previously untreated,

193 ation therapy and was well tolerated in each Phase III study, as well as in the pooled analysis, rega

194 ce/CALGB 50303 (NCT00118209), an intergroup, phase III study, compared dose-adjusted etoposide, predn

195 Given the premature termination of the phase III study, this supports the need for further defi

196 The IELSG-19 phase III study, to our knowledge, was the first such st

197 TISSE was a randomized, open-label, adaptive phase III study.

198 oposes ideas for further improvement in blue phase III technology to make it feasible for commerciali

199 In the revised design (phase III), the overall performance of participants impr

200 Phase III: the safety, efficacy, and durability at 30 da

201 metry; fasted and fed contraction frequency, phase III time) and secretion (transmural potential diff

202 The SAKK trial 75/08 was a multicenter phase III trial (NCT01107639) comparing induction chemot

203 In a recent phase III trial (NCT02020889) 53% of mepolizumab-treated

204 The prospective phase III trial ABCSG-28 (POSYTIVE) could not demonstrat

205 This article provides an overview of the phase III trial and delineates the different study arms

206 This randomized phase III trial compared lenalidomide as maintenance the

207 Our phase III trial compared neoadjuvant versus concurrent i

208 randomized, double-blind, placebo-controlled phase III trial conducted in 12 European countries inclu

209 double-blind, randomized, placebo-controlled Phase III trial conducted in a university hospital.

210 This phase III trial enrolled adult patients with brain metas

211 mor, and only four randomized trials and one phase III trial have been completed so far, all in the f

212 In this randomized phase III trial in 16 centers, patients with resectable

213 In PARADIGMS, a double-blind phase III trial in 215 paediatric patients with multiple

214 thout a leukotriene receptor antagonist in a phase III trial in adolescent patients with moderate sym

215 dary outcomes in clinical trials, an ongoing phase III trial in patients with diabetic kidney disease

216 E1609 was a phase III trial in patients with resected cutaneous mela

217 same domains that had at least one completed phase III trial in the same time frame, but failed to re

218 Methods This randomized, double-blind, phase III trial included AI-treated postmenopausal women

219 The multicenter randomized phase III trial included patients with cutaneous melanom

220 ducted a post hoc analysis of the vandetanib phase III trial involving patients with advanced medulla

221 A phase III trial is now underway to formally determine wh

222 Further investigation in a phase III trial is underway.

223 ernational, open-label randomized controlled phase III trial of adjuvant combination chemotherapy com

224 and target population were identified for a phase III trial of IMGN853 monotherapy in patients with

225 ction adenocarcinoma, Intergroup Trial 0116 (Phase III trial of postoperative adjuvant radiochemother

226 dose escalation by post hoc analysis of the phase III trial of rupatadine for Japanese patients with

227 or more controller medications, in the first phase III trial of tiotropium in children with severe sy

228 pective, multicenter, open-label, randomized phase III trial that compared a busulfan-based RIC with

229 CALGB/SWOG 80405 is a phase III trial that compared the addition of bevacizuma

230 CALGB/SWOG 80405 was a randomized phase III trial that found no statistically significant

231 address this point, we designed a randomized phase III trial to compare rituximab plus cyclophosphami

232 mRNA-1273 is currently in a phase III trial to evaluate its efficacy.

233 We report a prospective, double-blind phase III trial to investigate the effect of ATLG (Neovi

234 lticenter, double-blind, placebo-controlled, phase III trial was conducted across 39 centers in 13 co

235 ng results in phase II studies, a randomized phase III trial was designed to assess the efficacy of a

236 CPP FAP-310, a randomized, double-blind, Phase III trial was designed to examine the safety and e

237 The aim of this pivotal phase III trial was to demonstrate the efficacy and safe

238 and Methods In this multicenter, open-label, phase III trial, 2,012 women with early TOP2A-normal bre

239 ive probability of success in a hypothetical phase III trial, adjusting for biomarker covariates.

240 specimens collected as part of the Alliance phase III trial, C9581.

241 b (substudy of a larger GSK sponsored global phase III trial, MEA115575) where subjects received mepo

242 d Methods In this multicenter, double-blind, phase III trial, patients were randomly assigned (2:1) t

243 In this randomized phase III trial, patients who had local treatment of one

244 In a prospective, multicenter, randomized phase III trial, patients with cN0 early breast cancer o

245 In this international phase III trial, patients with stage IIIB or IV adenocar

246 In another phase III trial, the oral combination of netupitant and

247 In one phase III trial, the oral combination of netupitant and

248 In this open-label phase III trial, we evaluated the safety, tolerability,

249 ntrolled series, although was not in a small phase III trial.

250 vorable HL for this international randomized phase III trial.

251 the FDA for refractory MG on the basis of a phase III trial.

252 umab (arm B) in a 1:1 randomized, controlled phase III trial.

253 ently randomized stratified subgroup of this phase III trial.

254 lase for Intracerebral Hemorrhage Evacuation Phase III trial.

255 inating event to clinically definite MS in a phase III trial.

256 This was a randomized, open-label, phase III trial.

257 The VISION (phase III) trial will provide data of critical value to

258 olled in two independent European randomized phase III trials (IFM/DFCI2009 and EMN02/HO95).

259 Large Phase III trials across Asia and Latin America have rece

260 Phase III trials comparing non-vitamin K antagonist oral

261 om 22,654 patients enrolled in 28 randomized phase III trials contained in the ARCAD (Aide et Recherc

262 nstrate their efficacy and safety in pivotal phase III trials for registration.

263 odium falciparum malaria infection completed phase III trials in 2014 and demonstrated efficacy again

264 Two phase III trials in adult patients with non-small-cell l

265 With the initiation of large phase III trials investigating immunomodulatory drugs fo

266 igh SVR12 rates, equivalent to those seen in Phase III trials of other pangenotypic options, and has

267 s for HCC and ICC safely, supporting ongoing phase III trials of radiation in HCC and ICC.

268 logy of dengue viruses (DENV) in two pivotal phase III trials of the tetravalent dengue vaccine, CYD-

269 However, Phase III trials of this combination in other genotypes

270 Twin phase III trials showed significantly improved survival

271 se end points in five prospective randomized phase III trials that enrolled a total of 6,081 patients

272 820 men with mCRPC randomly assigned in nine phase III trials to DP or a DP-containing regimen were c

273 Seven published phase III trials were examined for prespecified design a

274 Two randomized phase III trials were identified, and individual patient

275 gression, and death obtained from randomized phase III trials were used to determine the likelihood o

276 Phase II trials) and pivotal, confirmatory (Phase III trials) testing.

277 of several studies (including two randomized phase III trials).

278 cell trophic factor BAFF, was ineffective in phase III trials, and efgartigimod, which depletes antib

279 There are only 2 phase III trials, both on remote ischemic conditioning i

280 In Phase III trials, rivaroxaban, apixaban, edoxaban (antif

281 were pooled from four studies, including two phase III trials, with patients who received nivolumab 3

282 Two phase III trials-the Trial Assigning Individualized Opti

283 overall survival (OS) benefit in randomized phase III trials.

284 ble formulation for HIV PrEP being tested in Phase III trials.

285 s) of action and enhance planning of pivotal Phase III trials.

286 sting that MDT should be explored further in phase III trials.

287 t vaccine Butantan-DV, which is currently in phase III trials.

288 finitions were chosen in accordance with the Phase III trials.

289 vaccine candidates, and many have moved into phase III trials.

290 sentative of the participating sites in both Phase III trials.

291 onary embolism, were underrepresented in the Phase III trials.

292 e as that observed in the three EV71 vaccine phase III trials.

293 new agents are currently being evaluated in phase III trials.

294 b monotherapy in clinical studies, including phase III trials; 86 (10%) had mucosal melanoma and 665

295 irreproducibility of results across pilot to Phase-III trials is population stratification bias cause

296 The phase III VISION trial represents the largest well-desig

297 for diabetic macular edema (DME) during the phase III VISTA DME trial were maintained with individua

298 al of the first tension-generating step, and phase III was not observed.

299 In phase III, we tested 1 redesigned layout with an additio

300 In phase III, we used findings from these pilots to impleme